Skip to content

Study · Observational study · n = 4,121 · 2025

9 results

Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials.

Giorgino F, Lingvay I, Van Gaal LF, Sharma P, Rodríguez Á, Kiljański J, Torcello-Gómez A, Levine JA

Diabetes care1 May 2025Cited by 4 (Europe PMC)

PMID40100982 (opens in a new tab)PMCIDPMC12034897 (opens in a new tab)DOI10.2337/dc24-2790 (opens in a new tab)PepBankPUB-40100982
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In tirzepatide-treated adults with type 2 diabetes, early weight responders had a larger HbA1c reduction at week 40/42 (-2.5%) than non-early responders (-2.2%).

    In plain wordsIn adults with type 2 diabetes on tirzepatide, those who lost weight early had a slightly larger HbA1c drop later than those who did not.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change at week 40/42 by early weight response
    Study

    n = 4,121

    Comparator
    Non-early responders
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 40 or 42 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.5%
    early weight responders
    HbA1c change
    −2.2%
    non-early weight responders

    Source sentences

    Summary
    Early versus nonearly responders in FSG or weight achieved better HbA1c (-2.6% vs. -2.0% or -2.5% vs. -2.2%, respectively) and weight (-11% vs. -10% or -15% vs. -8%, respectively) responses at week 40/42 and greater improvements in blood pressure and lipids profile.
    2 context sentences
    Summary · context
    This post hoc analysis used pooled data across trials.
    Summary · context
    Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.
  2. 02HumanObservational studyEfficacy outcome

    In tirzepatide-treated adults with type 2 diabetes, early weight responders had a larger weight reduction at week 40/42 (-15%) than non-early responders (-8%).

    In plain wordsIn adults with type 2 diabetes on tirzepatide, those who lost weight early lost more weight overall than those who did not.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight change at week 40/42 by early weight response
    Study

    n = 4,121

    Comparator
    Non-early responders
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 40 or 42 weeksAs given in this study (human).

    Measurements

    Weight change
    −15%
    early weight responders
    Weight change
    −8%
    non-early weight responders

    Source sentences

    Summary
    Early versus nonearly responders in FSG or weight achieved better HbA1c (-2.6% vs. -2.0% or -2.5% vs. -2.2%, respectively) and weight (-11% vs. -10% or -15% vs. -8%, respectively) responses at week 40/42 and greater improvements in blood pressure and lipids profile.
    2 context sentences
    Summary · context
    This post hoc analysis used pooled data across trials.
    Summary · context
    Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.
  3. 03HumanObservational studyEfficacy outcome

    In tirzepatide-treated adults with type 2 diabetes, early responders in fasting serum glucose had a larger HbA1c reduction at week 40/42 (-2.6%) than non-early responders (-2.0%).

    In plain wordsIn adults with type 2 diabetes on tirzepatide, those whose fasting glucose fell early had a larger HbA1c drop later than those who did not.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change at week 40/42 by early fasting glucose response
    Study

    n = 3,676

    Comparator
    Non-early responders
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 40 or 42 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.6%
    early FSG responders
    HbA1c change
    −2%
    non-early FSG responders

    Source sentences

    Summary
    Early versus nonearly responders in FSG or weight achieved better HbA1c (-2.6% vs. -2.0% or -2.5% vs. -2.2%, respectively) and weight (-11% vs. -10% or -15% vs. -8%, respectively) responses at week 40/42 and greater improvements in blood pressure and lipids profile.
    2 context sentences
    Summary · context
    This post hoc analysis used pooled data across trials.
    Summary · context
    Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.
  4. 04HumanObservational studyEfficacy outcome

    In tirzepatide-treated adults with type 2 diabetes, early fasting glucose responders had a larger weight reduction at week 40/42 (-11%) than non-early responders (-10%).

    In plain wordsIn adults with type 2 diabetes on tirzepatide, those whose fasting glucose fell early lost slightly more weight than those who did not.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight change at week 40/42 by early fasting glucose response
    Study

    n = 3,676

    Comparator
    Non-early responders
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 40 or 42 weeksAs given in this study (human).

    Measurements

    Weight change
    −11%
    early FSG responders
    Weight change
    −10%
    non-early FSG responders

    Source sentences

    Summary
    Early versus nonearly responders in FSG or weight achieved better HbA1c (-2.6% vs. -2.0% or -2.5% vs. -2.2%, respectively) and weight (-11% vs. -10% or -15% vs. -8%, respectively) responses at week 40/42 and greater improvements in blood pressure and lipids profile.
    2 context sentences
    Summary · context
    This post hoc analysis used pooled data across trials.
    Summary · context
    Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.
  5. 05HumanObservational studyEfficacy outcome

    In tirzepatide-treated adults with type 2 diabetes, early responders in fasting glucose or weight had greater improvements in blood pressure than non-early responders.

    In plain wordsIn adults with type 2 diabetes on tirzepatide, early responders had bigger blood pressure improvements than non-early responders.

    Peptide
    Tirzepatide
    Outcome
    Not applicableBlood pressure improvement by early response
    Study

    n: not reported in source

    Comparator
    Non-early responders
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 40 or 42 weeksAs given in this study (human).

    Source sentences

    Summary
    greater improvements in blood pressure and lipids profile.
    2 context sentences
    Summary · context
    This post hoc analysis used pooled data across trials.
    Summary · context
    Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.
  6. 06HumanObservational studyEfficacy outcome

    In tirzepatide-treated adults with type 2 diabetes, early responders in fasting glucose or weight had greater improvements in lipid profile than non-early responders.

    In plain wordsIn adults with type 2 diabetes on tirzepatide, early responders had bigger blood fat improvements than non-early responders.

    Peptide
    Tirzepatide
    Outcome
    Not applicableLipid profile improvement by early response
    Study

    n: not reported in source

    Comparator
    Non-early responders
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 40 or 42 weeksAs given in this study (human).

    Source sentences

    Summary
    greater improvements in blood pressure and lipids profile.
    2 context sentences
    Summary · context
    This post hoc analysis used pooled data across trials.
    Summary · context
    Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.
  7. 07HumanObservational studyEfficacy outcome

    In tirzepatide-treated adults with type 2 diabetes, non-early responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses.

    In plain wordsIn adults with type 2 diabetes on tirzepatide, people who did not respond early still had meaningful HbA1c and weight reductions.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c and weight reductions in non-early responders
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    all tirzepatide doses · 40 or 42 weeksAs given in this study (human).

    Source sentences

    Summary
    Nonearly responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses.
    2 context sentences
    Summary · context
    This post hoc analysis used pooled data across trials.
    Summary · context
    Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.
  8. 08HumanObservational studySafety outcome

    In tirzepatide-treated adults with type 2 diabetes, the incidence of generally mild to moderate gastrointestinal adverse events decreased over time.

    In plain wordsIn adults with type 2 diabetes on tirzepatide, stomach and gut side effects, mostly mild or moderate, became less frequent over time.

    Peptide
    Tirzepatide
    Outcome
    DecreaseIncidence of gastrointestinal adverse events over time
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 40 or 42 weeksAs given in this study (human).

    Source sentences

    Summary
    The incidence of GI AEs (generally mild to moderate events) decreased over time
    2 context sentences
    Summary · context
    This post hoc analysis used pooled data across trials.
    Summary · context
    Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.
  9. 09HumanObservational studySafety outcome

    In tirzepatide-treated adults with type 2 diabetes, gastrointestinal adverse events were in general comparable between early and non-early responders.

    In plain wordsIn adults with type 2 diabetes on tirzepatide, stomach and gut side effects were about the same in early and non-early responders.

    Peptide
    Tirzepatide
    Outcome
    No significant changeGastrointestinal adverse events by early response
    Study

    n: not reported in source

    Comparator
    Non-early responders
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 40 or 42 weeksAs given in this study (human).

    Source sentences

    Summary
    was, in general, comparable between early and nonearly responders.
    2 context sentences
    Summary · context
    This post hoc analysis used pooled data across trials.
    Summary · context
    Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.